Amgen Plays Diversity Card In Approach To Cancer; Immunotherapy Could Be Its Ace
Amgen explains why it has what it takes in immunotherapy, as part of a broader oncology development plan.
You may also be interested in...
Amgen Amps Up T-VEC Story At ASCO With Filing Plans And Combos
Amgen will file the cancer immunotherapy talimogene laherparepvec for the treatment of metastatic melanoma later this year, although the product’s larger commercial potential likely lies om combination with other immunotherapies.
R&D Briefs: Alprolix Approval Bodes Well, T-VEC Stumbles, Curis Back On Track
FDA approves Biogen’s long-acting hemophilia drug Alprolix and lifts clinical hold on Curis’ cancer drug CUDC-427, but Amgen’s announcement that its melanoma vaccine T-VEC failed to improve survival clouds its chances with the agency.
R&D In Brief: Sucampo/Takeda, Amgen, Merck/Endocyte
Sucampo/Takeda stumble with new formulation of Amitiza; Amgen makes progress with melanoma vaccine T-Vec and PCSK9 inhibitor evolocumab; Merck/Endocyte see positive signs for vintafolide in lung cancer, positive opinion in ovarian.